HE4 is an independent prognostic marker in endometrial cancer patients

Gynecologic Oncology

Volumn 126, Issue 2, 2012, Pages 186-191

  Mutz Dehbalaie, Irene ^a   Egle, Daniel ^a   Fessler, Siegfried ^a   Hubalek, Michael ^a   Fiegl, Heidi ^a   Marth, Christian ^a   Widschwendter, Andreas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CA125; Endometrial cancer; HE4; Prognostic marker

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOLUMINESCENCE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOASSAY; LUMINESCENT MEASUREMENTS; MIDDLE AGED; PROGNOSIS; PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862886235     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.04.022     Document Type: Article

References (29)

1. Amant F,Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505. (Pubitemid 41111699)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56: 106-30.
3. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgicalpathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7. (Pubitemid 13194678)
5. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. Apmis 2009;117:693-707.
6. Huszar M, Pfeifer M, Schirmer U, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010;220:551-61.
7. Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas 2010;67:46-53.
8. Sood AK, Buller RE, Burger RA, et al. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441-7. (Pubitemid 27357939)
9. Lo SS, Cheng DK, Ng TY, et al. Prognostic significance of tumour markers in endometrial cancer. Tumour Biol 1997;18:241-9. (Pubitemid 27288430)
10. Price FV, Chambers SK, Carcangiu ML, et al. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer 1998;82:1720-5.
11. Soper JT, Berchuck A, Olt GJ, et al. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol 1990;163:1204-9. (Pubitemid 20377403)
12. Ginath S, Menczer J, Fintsi Y, et al. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer 2002;12:372-5. (Pubitemid 34839835)
13. Powell JL, Hill KA, Shiro BC, et al. Preoperative serum CA-125 levels in treating endometrial cancer. J Reprod Med 2005;50:585-90. (Pubitemid 41193137)
14. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8. (Pubitemid 351174295)
15. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
16. Moore RG, Brown AK, Miller MC, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008;110:196-201.
17. Moore RG, Miller CM, Brown AK, et al. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus. Int J Gynecol Cancer 2011;21:1185-90.
18. Bignotti E, Ragnoli M, Zanotti L, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011;104: 1418-25.
19. Ruggeri G, Bandiera E, Zanotti L, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011;412:1447-53.
20. Kalogera E, Scholler N, Powless C, et al. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol 2011.
21. Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-66.
22. Montagnana M, Lippi G, Ruzzenente O, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009;23:331-5.
23. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9.
24. Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20:2496-506.
25. Kamei M, Yamashita S, Tokuishi K, et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res 2010;30:4779-83.
26. Escudero JM, Auge JM, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-44.
27. Aalders JG, Thomas G. Endometrial cancer-revisiting the importance of pelvic and para aortic lymph nodes. Gynecol Oncol 2007;104:222-31. (Pubitemid 46054140)
28. Steffensen KD, Waldstrom M, Brandslund I, et al. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. Int J Gynecol Cancer 2011;21:1040-7.
29. Yamashita S, Tokuishi K, Hashimoto T, et al. Prognostic significance of HE4 expression in pulmonary adenocarcinoma. Tumour Biol 2011;32:265-71.